Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 474

1.

Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up.

Perez de Isla L, Alonso R, Watts GF, Mata N, Saltijeral Cerezo A, Muñiz O, Fuentes F, Diaz-Diaz JL, de Andrés R, Zambón D, Rubio-Marin P, Barba-Romero MA, Saenz P, Sanchez Muñoz-Torrero JF, Martinez-Faedo C, Miramontes-Gonzalez JP, Badimón L, Mata P; SAFEHEART Investigators.

J Am Coll Cardiol. 2016 Mar 22;67(11):1278-85. doi: 10.1016/j.jacc.2016.01.008.

2.

Attainment of LDL Cholesterol Treatment Goals in Children and Adolescents With Familial Hypercholesterolemia. The SAFEHEART Follow-up Registry.

Saltijeral A, Pérez de Isla L, Alonso R, Muñiz O, Díaz-Díaz JL, Fuentes F, Mata N, de Andrés R, Díaz-Soto G, Pastor J, Pinilla JM, Zambón D, Pinto X, Badimón L, Mata P; SAFEHEART Investigators.

Rev Esp Cardiol (Engl Ed). 2017 Jun;70(6):444-450. doi: 10.1016/j.rec.2016.10.010. Epub 2016 Nov 29. English, Spanish.

PMID:
27913073
3.

Target achievement with maximal statin-based lipid-lowering therapy in Korean patients with familial hypercholesterolemia: A study supported by the Korean Society of Lipid and Atherosclerosis.

Oh J, Lee CJ, Kim DI, Rhee MY, Lee BK, Ahn Y, Cho BR, Woo JT, Hur SH, Jeong JO, Jang Y, Lee SH.

Clin Cardiol. 2017 Dec;40(12):1291-1296. doi: 10.1002/clc.22826. Epub 2017 Dec 14.

4.

Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART).

Mata N, Alonso R, Badimón L, Padró T, Fuentes F, Muñiz O, Perez-Jiménez F, López-Miranda J, Díaz JL, Vidal JI, Barba A, Piedecausa M, Sanchez JF, Irigoyen L, Guallar E, Ordovas JM, Mata P.

Lipids Health Dis. 2011 Jun 10;10:94. doi: 10.1186/1476-511X-10-94.

5.

Ezetimibe Use and LDL-C Goal Achievement: A Retrospective Database Analysis of Patients with Clinical Atherosclerotic Cardiovascular Disease or Probable Heterozygous Familial Hypercholesterolemia.

Menzin J, Aggarwal J, Boatman B, Yu J, Stern K, Harrison DJ, Patel JG.

J Manag Care Spec Pharm. 2017 Dec;23(12):1270-1276. doi: 10.18553/jmcp.2017.16414. Epub 2017 Sep 25.

6.

Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.

Avellone G, Di Garbo V, Guarnotta V, Scaglione R, Parrinello G, Purpura L, Torres D, Campisi D.

Int Angiol. 2010 Dec;29(6):514-24.

PMID:
21173733
7.

Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry.

deGoma EM, Ahmad ZS, O'Brien EC, Kindt I, Shrader P, Newman CB, Pokharel Y, Baum SJ, Hemphill LC, Hudgins LC, Ahmed CD, Gidding SS, Duffy D, Neal W, Wilemon K, Roe MT, Rader DJ, Ballantyne CM, Linton MF, Duell PB, Shapiro MD, Moriarty PM, Knowles JW.

Circ Cardiovasc Genet. 2016 Jun;9(3):240-9. doi: 10.1161/CIRCGENETICS.116.001381. Epub 2016 Mar 24.

8.

Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey.

Krempf M, Simpson RJ Jr, Ramey DR, Brudi P, Giezek H, Tomassini JE, Lee R, Farnier M.

Lipids Health Dis. 2015 May 19;14:45. doi: 10.1186/s12944-015-0037-y.

9.

How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?

Masana L, Plana N, Pérez-Calahorra S, Ibarretxe D, Lamiquiz-Moneo I, Pedro-Botet J, Suárez-Tembra M, Valdivielso P, Ortega E, Civeira F; Dyslipidemia Registry of the Spanish Arteriosclerosis Society.

Atherosclerosis. 2017 Jul;262:107-112. doi: 10.1016/j.atherosclerosis.2017.05.013. Epub 2017 May 12.

PMID:
28531826
10.

Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades.

Elis A, Zhou R, Stein EA.

Am J Cardiol. 2011 Jul 15;108(2):223-6. doi: 10.1016/j.amjcard.2011.03.027. Epub 2011 May 3.

PMID:
21545982
11.

Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.

Cannon CP, Khan I, Klimchak AC, Reynolds MR, Sanchez RJ, Sasiela WJ.

JAMA Cardiol. 2017 Sep 1;2(9):959-966. doi: 10.1001/jamacardio.2017.2289.

12.

Identification and characterization of severe familial hypercholesterolemia in patients presenting for cardiac catheterization.

Zafrir B, Shapira C, Lavie G, Halon DA, Flugelman MY.

J Clin Lipidol. 2016 Nov - Dec;10(6):1338-1343. doi: 10.1016/j.jacl.2016.08.010. Epub 2016 Aug 27.

PMID:
27919350
13.

Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom.

Cao X, Ejzykowicz F, Ramey DR, Sajjan S, Ambegaonkar BM, Mavros P, Tunceli K.

Clin Ther. 2015 Apr 1;37(4):804-15. doi: 10.1016/j.clinthera.2014.12.019. Epub 2015 Jan 24.

PMID:
25626487
14.

Improving the Monitoring and Care of Patients With Familial Hypercholesterolemia.

Hegele RA.

J Am Coll Cardiol. 2016 Mar 22;67(11):1286-8. doi: 10.1016/j.jacc.2016.01.041. No abstract available.

15.

Efficacy and safety of coadministration of rosuvastatin, ezetimibe, and colestimide in heterozygous familial hypercholesterolemia.

Kawashiri MA, Nohara A, Noguchi T, Tada H, Nakanishi C, Mori M, Konno T, Hayashi K, Fujino N, Inazu A, Kobayashi J, Mabuchi H, Yamagishi M.

Am J Cardiol. 2012 Feb 1;109(3):364-9. doi: 10.1016/j.amjcard.2011.09.019. Epub 2011 Nov 22.

PMID:
22112743
16.

[LDL-cholesterol control in patients with genetic dyslipidemia followed up by Lipid and Vascular Risk Units of the Spanish Society of Arteriosclerosis].

Lahoz C, Mostaza JM, Pintó X, de la Cruz JJ, Banegas JR, Pedro-Botet J; grupo de investigadores EDICONDIS-ULISEA.

Clin Investig Arterioscler. 2015 Jan-Feb;27(1):1-8. doi: 10.1016/j.arteri.2014.04.001. Epub 2014 Jun 2. Spanish.

PMID:
24882148
17.

Clinical determinants and treatment gaps in familial hypercholesterolemia: Data from a multi-ethnic regional health service.

Zafrir B, Jubran A, Lavie G, Halon DA, Flugelman MY, Shapira C.

Eur J Prev Cardiol. 2017 May;24(8):867-875. doi: 10.1177/2047487317693132. Epub 2017 Feb 10.

PMID:
28186442
18.

Combination therapy analysis of ezetimibe and statins in Chinese patients with acute coronary syndrome and type 2 diabetes.

Li L, Zhang M, Su F, Li Y, Shen Y, Shen J, Zhang D.

Lipids Health Dis. 2015 Feb 18;14:10. doi: 10.1186/s12944-015-0004-7.

19.

Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations.

Stein EA, Dann EJ, Wiegman A, Skovby F, Gaudet D, Sokal E, Charng MJ, Mohamed M, Luirink I, Raichlen JS, Sundén M, Carlsson SC, Raal FJ, Kastelein JJP.

J Am Coll Cardiol. 2017 Aug 29;70(9):1162-1170. doi: 10.1016/j.jacc.2017.06.058.

20.

A 10-year experience using combined lipid-lowering pharmacotherapy in children and adolescents.

Araujo MB, Pacce MS.

J Pediatr Endocrinol Metab. 2016 Nov 1;29(11):1285-1291. doi: 10.1515/jpem-2016-0117.

PMID:
27718491

Supplemental Content

Support Center